QGEN vs TMO vs BIO Stock Comparison

Qiagen, Thermo Fisher Scientific and Bio-Rad Laboratories Prices as of Nov 13, 2026 Peers: Industry group
QGEN Qiagen N.V.
$49.90 +9.6% 1M +6.2% 1Y
Market cap
$10.84B
P/E
28.2x
Revenue (TTM)
$2.12B
Div. yield
–
Life Sciences Tools Healthcare
2 wins

Head to Head

11 decided of 12

Thermo Fisher Scientific leads on 6 of the 12 questions below (Thermo Fisher Scientific 6, Bio-Rad Laboratories 3, Qiagen 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionQGENTMOBIOLeader
Larger companyMarket capitalisation $10.84B $257.71B $9.73B TMO
Cheaper on earningsLower P/E, profitable companies only 28.2x 36.4x 9.5x BIO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.2x 27.0x 36.0x QGEN
Faster revenue growthRevenue growth, trailing twelve months +2.2% +8.3% +1.4% TMO
More profitableNet margin, trailing twelve months 18.2% 14.9% 39.5% BIO
Better return on capitalReturn on invested capital 7.4% 8.0% -0.6% TMO
Less leveragedLower net debt / EBITDA 1.2x 3.1x — QGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +6.2% +20.7% +15.5% TMO
Better 5-year returnAnnualised price return, 5 years -3.6%/yr +2.0%/yr -13.5%/yr TMO
Less volatileAnnualised volatility, 1 year 35.2% 30.7% 36.5% TMO
Higher overall scoreMean of the five percentile scores vs peers 69/100 60/100 70/100 BIO

Percentile Scorecard

QGENTMOBIO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisQGENTMOBIO
Valuation 74 #63 of 243 62 #94 of 243 85 #38 of 243
Growth 25 #171 of 228 41 #136 of 228 48 #120 of 228
Profitability 93 #16 of 222 82 #40 of 222 70 #67 of 222
Financial Health 60 #100 of 248 31 #172 of 248 66 #85 of 248
Shareholder Returns 94 #11 of 158 82 #29 of 158 80 #32 of 158
Overall 69 60 70
  • QGEN ranked among 252 companies in Medical Devices and Diagnostics
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • BIO ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodQGENTMOBIOSPY
1 month +9.6%+4.0%+1.0% -2.0%
3 months +16.2%+19.1%+2.8% -2.8%
6 months +51.3%+59.7%+47.9% +2.0%
Year to date +5.4%+20.8%+20.8% +10.6%
1 year +6.2%+20.7%+15.5% +12.2%
3 years +13.0%+52.5%+19.1% +68.1%
3 years, per year +4.2%+15.1%+6.0% +18.9%
5 years -16.9%+10.2%-51.6% +61.4%
5 years, per year -3.6%+2.0%-13.5% +10.1%
10 years +56.5%+362.9%+119.6% +248.5%
10 years, per year +4.6%+16.6%+8.2% +13.3%

Risk

MeasureQGENTMOBIOSPY
Volatility, 1Y 35.2%30.7%36.5% 13.6%
Downside volatility, 1Y 29.7%29.2%35.6% 13.9%
Beta vs S&P 500, 1Y 0.380.710.75 1.00
Return / volatility, 1Y 0.180.670.43 0.90
Max drawdown, 5Y -48.2%-41.5%-72.2% -25.4%
From 52-week high -10.3%-3.0%-6.2% -3.2%
52-week high $55.66$721.63$390.34 $779.14
52-week low $32.63$438.34$241.71 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleQGENTMOBIO
P/E now vs peer median 28.2xmedian 26.5x 36.6xmedian 26.5x 9.6xmedian 26.5x
P/S now vs peer median 5.1xmedian 2.7x 5.5xmedian 2.7x 3.8xmedian 2.7x
EV/EBITDA now vs peer median 17.7xmedian 18.4x 25.5xmedian 18.4x —median 18.4x
P/FCF now vs peer median 11.2xmedian 25.4x 34.2xmedian 25.4x 29.9xmedian 25.4x
P/B now vs peer median 3.1xmedian 2.5x 4.7xmedian 2.5x 1.3xmedian 2.5x
PEG now vs peer median 11.74median 0.98 4.84median 0.98 0.09median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsQGENTMOBIO
Revenue $2.12B $47.35B $2.59B
Gross profit $1.33B $19.45B $1.33B
Operating income $448.74M $8.47B -$61.90M
Net income $384.93M $7.09B $1.02B
Free cash flow $964.47M $7.60B $329.10M
R&D $199.87M $1.40B $265.80M
EPS (diluted) $1.76 $19.06 $37.96
Cash & equivalents $805.13M $5.46B $465.30M
Total debt $1.64B $41.37B $1.20B
Shares (diluted) 218.88M 371.00M 26.95M
Enterprise value $7.47B $234.22B $3.34B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricQGENTMOBIO
P/E 28.2x 36.6x 9.6x
P/FCF 11.2x 34.2x 29.9x
P/Operating cash flow 17.0x 27.8x 21.0x
P/S 5.1x 5.5x 3.8x
P/B 3.1x 4.7x 1.3x
P/Tangible book 3.4x 7.1x 1.3x
EV/EBITDA 17.7x 25.5x –
EV/EBIT 25.9x 34.8x -151.6x
EV/Revenue 5.5x 6.2x 3.6x
EV/FCF 12.1x 38.8x 28.5x
EV/Operating cash flow 18.3x 31.6x 20.1x
PEG (3Y EPS CAGR) 11.74 4.84 0.09

Growth

14 metrics
MetricQGENTMOBIO
Revenue growth (1Y) 2.2% 8.3% 1.4%
Revenue CAGR (3Y) 2.7% 2.9% -1.6%
Gross profit growth (1Y) 1.7% 7.8% -0.6%
Gross profit CAGR (3Y) 2.5% 4.0% -3.0%
Operating income growth (1Y) -7.6% 12.8% -127.6%
Operating income CAGR (3Y) 3.6% 7.2% -29.5%
Net income growth (1Y) -2.8% 7.9% 251.3%
Net income CAGR (3Y) 5.0% 6.2% 103.5%
EPS growth (1Y) -7.3% 9.7% 251.2%
EPS CAGR (3Y) 2.4% 7.6% 107.7%
Operating cash flow growth (1Y) -3.4% 21.9% -4.8%
Operating cash flow CAGR (3Y) 13.7% 4.5% 7.8%
Free cash flow growth (1Y) 1.1% 24.3% -2.3%
Free cash flow CAGR (3Y) 13.5% 5.1% 13.6%

Profitability

14 metrics
MetricQGENTMOBIO
Gross margin 62.8% 41.1% 51.3%
EBITDA margin 31.0% 24.4% –
Operating margin 21.2% 17.9% -2.4%
Pretax margin 21.7% 16.7% 50.9%
Net margin 18.2% 14.9% 39.5%
FCF margin 45.6% 16.0% 12.7%
Operating cash flow margin 30.0% 19.7% 18.1%
Return on equity 11.3% 13.2% 13.8%
Return on assets 6.5% 6.2% 9.7%
Return on invested capital 7.4% 8.0% -0.6%
Return on capital employed 8.5% 8.5% -0.6%
Asset turnover 0.4x 0.4x 0.2x
Cash conversion (OCF / net income) 1.6x 1.3x 0.5x
Stock comp / revenue 2.0% 0.7% 2.4%

Financial Health

11 metrics
MetricQGENTMOBIO
Debt / assets 27.6% 36.2% 11.2%
Debt / equity 0.5x 0.8x 0.2x
Net debt / EBITDA 1.2x 3.1x –
Debt / FCF 1.7x 5.4x 3.7x
Liabilities / assets 41.5% 52.1% 29.5%
Equity / assets 58.5% 47.9% 70.5%
Interest coverage 10.8x 12.0x -1.3x
Current ratio 2.6x 1.8x 3.2x
Quick ratio 1.9x 1.2x 2.2x
Cash ratio 1.3x 0.4x 1.7x
Altman Z-score 4.14 4.18 3.41

Shareholder Returns

7 metrics
MetricQGENTMOBIO
Dividend yield 5.3% 0.3% –
Net buyback yield 0.6% 1.6% 0.7%
Shareholder yield 5.9% 1.8% 0.7%
Payout ratio (earnings) – 9.5% –
Payout ratio (FCF) – 8.9% –
Dividend growth (1Y) – 8.0% –
Dividend CAGR (3Y) – 10.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusQGENTMOBIO
Forward P/E 21.2xFY2026 27.0xFY2026 36.0xFY2026
EPS, next fiscal year $2.35FY2026 $25.92FY2026 $10.18FY2026
EPS growth, next FY -1.3%FY2026 +13.3%FY2026 +2.6%FY2026
EPS growth, the year after +17.9% +2.2% -0.2%
Revenue, next fiscal year $2.25BFY2026 $50.12BFY2026 $2.69BFY2026
Revenue growth, next FY +7.8%FY2026 +12.5%FY2026 +4.2%FY2026
Revenue growth, the year after -2.8% -2.7% -7.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersQGENTMOBIO
Held by institutions 67.3% 90.2% 89.5%
Institutions holding 338 2,627 405
Change in shares held, QoQ +16.5% +0.8% -2.9%
Institutions buying 216 1,145 177
Institutions selling 86 1,145 157
Buyers to sellers 2.51 1.00 1.13

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

QGENTMOBIO
QGEN 1.00 0.44 0.41
TMO 0.44 1.00 0.59
BIO 0.41 0.59 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, QGEN, TMO and BIO?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Qiagen (QGEN) $10.84B, Thermo Fisher Scientific (TMO) $257.71B, Bio-Rad Laboratories (BIO) $9.73B.

Which stock is cheaper, QGEN, TMO and BIO?

Bio-Rad Laboratories (BIO) trades on the lowest price-to-earnings ratio (Qiagen (QGEN) 28.2x, Thermo Fisher Scientific (TMO) 36.4x, Bio-Rad Laboratories (BIO) 9.5x). On next year's consensus earnings, Qiagen (QGEN) is cheapest (Qiagen (QGEN) 21.2x, Thermo Fisher Scientific (TMO) 27.0x, Bio-Rad Laboratories (BIO) 36.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Qiagen (QGEN) +2.2%, Thermo Fisher Scientific (TMO) +8.3%, Bio-Rad Laboratories (BIO) +1.4%.

Which company is more profitable?

Bio-Rad Laboratories (BIO) has the highest net margin (Qiagen (QGEN) 18.2%, Thermo Fisher Scientific (TMO) 14.9%, Bio-Rad Laboratories (BIO) 39.5%). On return on invested capital, Thermo Fisher Scientific (TMO) leads (Qiagen (QGEN) 7.4%, Thermo Fisher Scientific (TMO) 8.0%, Bio-Rad Laboratories (BIO) -0.6%).

Which stock has performed better?

Over the past year Thermo Fisher Scientific (TMO) returned the most: Qiagen (QGEN) +6.2%, Thermo Fisher Scientific (TMO) +20.7%, Bio-Rad Laboratories (BIO) +15.5%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Qiagen (QGEN) -3.6%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr, Bio-Rad Laboratories (BIO) -13.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Qiagen (QGEN) 0.00%, Thermo Fisher Scientific (TMO) 0.00%, Bio-Rad Laboratories (BIO) 0.00%. Qiagen (QGEN) and Bio-Rad Laboratories (BIO) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Qiagen (QGEN) 35.2%, Thermo Fisher Scientific (TMO) 30.7%, Bio-Rad Laboratories (BIO) 36.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, QGEN, TMO and BIO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Thermo Fisher Scientific (TMO) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.